AAAAAA

   
Results: 1-8 |
Results: 8
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks
Authors: Rothenberg, ML Kuhn, JG Schaaf, LJ Rodriguez, GI Eckhardt, SG Villalona-Calero, MA Rinaldi, DA Hammond, LA Hodges, S Sharma, A Elfring, GL Petit, RG Locker, PK Miller, LL von Hoff, DD
Citation: Ml. Rothenberg et al., Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks, ANN ONCOL, 12(11), 2001, pp. 1631-1641
Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer
Authors: Socinski, MA Sandler, AB Miller, LL Locker, PK Hanover, CK Elfring, GL Israel, VK Pirotta, N Natale, RB
Citation: Ma. Socinski et al., Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer, J CL ONCOL, 19(4), 2001, pp. 1078-1087
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Authors: Saltz, LB Cox, JV Blanke, C Rosen, LS Fehrenbacher, L Moore, MJ Maroun, JA Ackland, SP Locker, PK Pirotta, N Elfring, GL Miller, LL
Citation: Lb. Saltz et al., Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer., N ENG J MED, 343(13), 2000, pp. 905-914
Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer
Authors: DeVore, RF Johnson, DH Crawford, J Garst, J Dimery, IW Eckardt, J Eckhardt, SG Elfring, GL Schaaf, LJ Hanover, CK Miller, LL
Citation: Rf. Devore et al., Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer, J CL ONCOL, 17(9), 1999, pp. 2710-2720
Irinotecan therapy in adults with recurrent or progressive malignant glioma
Authors: Friedman, HS Petros, WP Friedman, AH Schaaf, LJ Kerby, T Lawyer, J Parry, M Houghton, PJ Lovell, S Rasheed, K Cloughsey, T Stewart, ES Colvin, OM Provenzale, JM McLendon, RE Bigner, DD Cokgor, I Haglund, M Rich, J Ashley, D Malczyn, J Elfring, GL Miller, LL
Citation: Hs. Friedman et al., Irinotecan therapy in adults with recurrent or progressive malignant glioma, J CL ONCOL, 17(5), 1999, pp. 1516-1525
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors
Authors: Drengler, RL Kuhn, JG Schaaf, LJ Rodriguez, GI Villalona-Calero, MA Hammond, LA Stephenson, JA Hodges, S Kraynak, MA Staton, BA Elfring, GL Locker, PK Miller, LL Von Hoff, DD Rothenberg, ML
Citation: Rl. Drengler et al., Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors, J CL ONCOL, 17(2), 1999, pp. 685-696
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
Authors: Rothenberg, ML Cox, JV DeVore, RF Hainworth, JD Pazdur, R Rivkin, SE Macdonald, JS Geyer, CE Sandbach, J Wolf, SL Mohrland, JS Elfring, GL Miller, LL Von Hoff, DD
Citation: Ml. Rothenberg et al., A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma, CANCER, 85(4), 1999, pp. 786-795
Phase I clinical and pharmacologic study of weekly cisplatin combined withweekly irinotecan in patients with advanced solid tumors
Authors: Saltz, LB Spriggs, D Schaaf, LJ Schwartz, GK Ilson, D Kemeny, N Kanowitz, J Steger, C Eng, M Albanese, P Semple, D Hanover, CK Elfring, GL Miller, LL Kelsen, D
Citation: Lb. Saltz et al., Phase I clinical and pharmacologic study of weekly cisplatin combined withweekly irinotecan in patients with advanced solid tumors, J CL ONCOL, 16(12), 1998, pp. 3858-3865
Risultati: 1-8 |